SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing volatility as investors weigh a bottom-line earnings beat against persistent revenue softness and sluggish growth in key markets like China. The community is sharply divided, with some buyers accumulating at multi-year lows in anticipation of a long-term brand turnaround, while critics argue that changing consumer preferences and poor management make the stock a value trap.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as shareholders react to a record-breaking delivery performance and strong brand growth, despite broader market skepticism and institutional selling pressure. Investors are actively debating whether these strong fundamentals will finally catalyze a sustained recovery or if the stock will remain trapped by geopolitical concerns and algorithmic trading.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing significant volatility as investors debate the competitive impact of the new Open USD stablecoin consortium and monitor ongoing legislative efforts surrounding the Clarity Act. Community sentiment is deeply divided, with some traders viewing the current price decline as an attractive entry point for long-term accumulation, while others express frustration over institutional selling and intense competition from major payment networks.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors digest a fresh NASA contract worth up to $148.3 million for lunar lander development, sparking intense debate over the company's long-term infrastructure pipeline. While some community members view the award as vital validation of the firm's role in the Artemis program, others are closely monitoring high short interest and volatility as the stock seeks to stabilize following a period of sector-wide pressure.

Cantor Equity Partners II, Inc. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on November 11, 2020 and is headquartered in New York, NY.

Cantor Equity Partners II Inc. - Ordinary Shares - Class A

Cantor Equity Partners II Inc

Cantor Equity Partners II is gaining momentum as investors anticipate its merger with Securitize, a leader in institutional-grade real-world asset (RWA) tokenization backed by firms like BlackRock and Morgan Stanley. The community is focused on the upcoming ticker change to SECZ, viewing it as a pivotal infrastructure play for tokenized equities and stablecoins as the sector shifts toward regulated, on-chain financial services.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate its role as a defensive "orchestration layer" for enterprise AI, with many pointing to its significant short interest and deep cash reserves as potential catalysts for a squeeze. While community sentiment is polarized by stagnant price action, supporters highlight the company's transition into agentic AI and governance as a critical, undervalued moat.

ETF Opportunities Trust - Roundhill T-REX 2X Long DRAM Daily Target ETF

T-REX 2X Long DRAM Daily Target ETF

Investors are actively debating the merits of the newly launched RAM, a 2X leveraged ETF tracking DRAM, as the market weighs high-beta exposure against the inherent volatility and decay risks of leveraged products. The community is heavily focused on whether the broader AI-driven memory supercycle can sustain the aggressive momentum that followed the fund's recent debut.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is surging on high volume and heavy investor sentiment following a significant new multi-year commercialization partnership for prostate cancer treatment. The community is actively celebrating the deal as a major validation of the company's proprietary cancer-destroying platform and a key milestone in their broader path toward U.S. market commercialization.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLA Corp. is trending due to broad institutional momentum across the semiconductor equipment sector, fueled by synchronized institutional buying and strong expectations for AI infrastructure and memory capacity expansion. While some market participants are expressing concerns about overextended valuations and sector-wide repricing risks, community discussion remains heavily focused on the stock's role as a critical bottleneck in the fabrication supply chain.

AirJoule Technologies Corp. operates as a thermal energy and water harvesting technology company. It provides efficient and sustainable air conditioning and pure water from air through its transformational AirJoule technology. The company was founded on March 14, 2024 and is headquartered in Ronan, MT.

AirJoule Technologies Corp. - Ordinary Shares - Class A

AirJoule Technologies is seeing significant investor attention driven by rising volume and the company's strategic focus on atmospheric water generation for AI data centers and industrial cooling. Community members are actively debating the potential of its waste-heat technology while closely monitoring for upcoming commercialization milestones and updates from major partners like GE Vernova.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma PR Newswire SAN DIEGO, June 15, 2026 No filing review issues identified by FDA with PDUFA...

Inhibrx Reports First Quarter 2026 Financial Results

Inhibrx Reports First Quarter 2026 Financial Results Inhibrx Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx...

Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study

Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study...

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.read more...

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy Inhibrx Reports Interim Phase 2 Data for...

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon...

Credit Industriel ET Commercial Sells 20,302 Shares of Inhibrx Biosciences, Inc. $INBX

Credit Industriel ET Commercial decreased its position in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) by 70.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,656 shares of...

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives Average Rating of "Hold" from Brokerages

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) has received an average recommendation of 'Hold' from the six brokerages that are currently covering the firm, MarketBeat.com reports. One...

Inhibrx Biosciences (NASDAQ:INBX) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised shares of Inhibrx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday...

Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer

Inhibrx Biosciences (NASDAQ:INBX) shared a clinical update on ozekibart in advanced colorectal cancer, highlighting Phase I/II data evaluating ozekibart in combination with FOLFIRI in a heavily...

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

INBX Stock Hit Record Highs: Cancer Therapies Reportedly Draw Big Pharma Interest

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

INBXInhibrx Inc

Fundamentals

Latest INBX News